Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631086 | 1.00 | DDB1 (0.59) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL26633418 | 1.00 | DDB1 (0.59) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL24671227 | 0.89 | DDB1 (0.61) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL30796982 | 0.85 | DDB1 (0.51) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL27451515 | 0.85 | DDB1 (0.51) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL30797050 | 0.83 | DDB1 (0.55) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL27451514 | 0.83 | DDB1 (0.55) | DDB1CRBNPDK4NAMPTCDK7 | |
| SCHEMBL30631026 | 0.81 | DDB1 (0.66) | DDB1CRBNNAMPT | |
| SCHEMBL26633417 | 0.81 | DDB1 (0.66) | DDB1CRBNNAMPT | |
| SCHEMBL26633409 | 0.81 | DDB1 (0.66) | DDB1CRBNNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050577-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SHANGHAI) PHARMA ENG CO., LTD. (CN) | 2024-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050577-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | CDKL1, CDKL2, CDKL3 | DDB1 199/4885CRBN 347/4885PDK4 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.